Home / Health / NY Medicaid Coverage for Cancer Tests at Risk
NY Medicaid Coverage for Cancer Tests at Risk
8 Apr
Summary
- New York expanded biomarker testing access three years ago.
- Governor's budget proposal may restrict Medicaid coverage.
- Advocates and cancer survivors urge lawmakers to reject the proposal.
New York state's significant advancement in cancer care access, achieved three years ago through expanded biomarker testing, faces potential setbacks. Advocates are concerned that the current budget proposal by Governor Kathy Hochul could undermine this progress for individuals covered by Medicaid.
In 2023, legislation was enacted requiring insurance providers, including Medicaid, to cover biomarker testing. However, the governor's current budget proposal introduces a "medical necessity criteria" requirement for Medicaid enrollees, raising alarms among healthcare advocates. This move is seen by many as a step backward for patient access to potentially life-saving diagnostics.
Cancer survivors and advocacy groups have voiced strong opposition, gathering to urge state lawmakers to reject the proposed changes. They emphasize that biomarker testing has been integral to their treatment plans and survival. Beyond cancer patients, advocates highlight that this type of testing is crucial for understanding and treating a wide range of diseases, including those currently without cures.
